Ignite Creation Date:
2024-05-06 @ 5:41 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05399277
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2022-05-26
Brief Title:
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion CAPITAL-RAPTOR
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion CAPITAL-RAPTOR
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Transradial access TRA is the preferred vascular access site for invasive coronary angiography TRA is limited by blockage of the radial artery post-procedurally preventing future use of TRA This is referred to as radial artery occlusion RAO and occurs in 5 of cases While intraprocedural anticoagulation has been studied extensively to mitigate this complication oral anticoagulation post-TRA has not The investigators will assess the impact of a one-week course of rivaroxaban post-TRA to reduce the rate of ultrasound-defined RAO at 30 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None